|
Optimizing Tumor-Reactive γδ T Cells for Antibody-Based Cancer Immunotherapy. |
|
Τετάρτη, 13 Οκτώβριος 2010 06:15 |
 |
 |
 |
|
Authors: Meraviglia S, Caccamo N, Guggino G, Tolomeo M, Siragusa S, Stassi G, Dieli F
Monoclonal antibodies (mAbs) constitute the most rapidly growing class of human therapeutics and the second largest class of drugs after vaccines. The treatment of B-cell malignancies and HER2/Neu(+) breast cancer has benefited considerably from the use of therapeutic mAbs, either alone or in combination with standard chemotherapy. Frequent relapses, however, demonstrate that the bioactivity of these mAbs is still suboptimal. The concept of improving the anti-tumor activity of mAbs is well established and potentiating the cytotoxicity induced by anticancer mAbs can be achieved by strategies that target the downstream cytolytic effector cells. The recruitment of Fcγ receptor-dependent functions appear...
Source: www.medworm.com
|
